Literature DB >> 15916982

A mouse model of carcinoid syndrome and heart disease.

Sandeepa Musunuru1, Jennifer E Carpenter, Rebecca S Sippel, Muthusamy Kunnimalaiyaan, Herbert Chen.   

Abstract

BACKGROUND: Carcinoid heart disease occurs in over 65% of patients with the carcinoid syndrome and is characterized by fibrous thickening of cardiac valves, leading to heart failure. Whether serotonin is directly responsible for these cardiac abnormalities is unknown. Therefore, to further understand the etiology and pathophysiology of carcinoid heart disease, we developed an animal model of the carcinoid syndrome.
MATERIALS AND METHODS: Seventeen nude mice underwent intrasplenic injection of human pancreatic carcinoid BON cells (10(7)) and then were euthanized 9 weeks later. Murine livers were analyzed by immunohistochemistry. Murine hearts were sectioned and the surface area of the right heart valves determined. Blood was also collected and analyzed for platelet serotonin by ELISA.
RESULTS: Sixty-five percent of the mice developed gross carcinoid liver metastases demonstrated by chromogranin-A-staining lesions within the liver. Mice with carcinoid liver metastases had elevated platelet serotonin levels (1058 +/- 529 ng/ml versus 123 +/- 52 ng/ml, P = 0.002) when compared to the controls. Animals with carcinoid liver metastases also had a trend toward greater tricuspid valvular surface areas (242 +/- 24 versus 174 +/- 25 microm, P = 0.08). On histological examination, this increase in tricuspid surface area in mice with liver metastases appeared to be due to fibrosis of the valvular tissues, consistent with the pathologic findings of carcinoid heart disease.
CONCLUSIONS: Using this novel animal model of carcinoid syndrome, the tricuspid valve thickening resembling carcinoid heart disease could be due to exposure to factors such as serotonin secreted by carcinoid tumor cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15916982     DOI: 10.1016/j.jss.2005.01.003

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  12 in total

1.  Identification and validation of Notch pathway activating compounds through a novel high-throughput screening method.

Authors:  Scott N Pinchot; Renata Jaskula-Sztul; Li Ning; Noel R Peters; Mackenzie R Cook; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

Review 2.  Carcinoid-syndrome: recent advances, current status and controversies.

Authors:  Tetsuhide Ito; Lingaku Lee; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2018-02       Impact factor: 3.243

Review 3.  Translational research in neuroendocrine tumors: pitfalls and opportunities.

Authors:  J Capdevila; O Casanovas; R Salazar; D Castellano; A Segura; P Fuster; J Aller; R García-Carbonero; P Jimenez-Fonseca; E Grande; J P Castaño
Journal:  Oncogene       Date:  2016-09-19       Impact factor: 9.867

4.  Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian National Expert Group.

Authors:  W Kocha; J Maroun; H Kennecke; C Law; P Metrakos; J F Ouellet; R Reid; C Rowsell; A Shah; S Singh; S Van Uum; R Wong
Journal:  Curr Oncol       Date:  2010-06       Impact factor: 3.677

5.  Raf-1 activation in gastrointestinal carcinoid cells decreases tumor cell adhesion.

Authors:  David Yü Greenblatt; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  Am J Surg       Date:  2007-03       Impact factor: 2.565

Review 6.  Fibrosis and carcinoid syndrome: from causation to future therapy.

Authors:  Maralyn Druce; Andrea Rockall; Ashley B Grossman
Journal:  Nat Rev Endocrinol       Date:  2009-05       Impact factor: 43.330

Review 7.  Carcinoid tumors.

Authors:  Scott N Pinchot; Kyle Holen; Rebecca S Sippel; Herbert Chen
Journal:  Oncologist       Date:  2008-12-17

8.  Fenfluramine disrupts the mitral valve interstitial cell response to serotonin.

Authors:  Jeanne M Connolly; Marina A Bakay; James T Fulmer; Robert C Gorman; Joseph H Gorman; Mark A Oyama; Robert J Levy
Journal:  Am J Pathol       Date:  2009-08-13       Impact factor: 4.307

9.  Tautomycin suppresses growth and neuroendocrine hormone markers in carcinoid cells through activation of the Raf-1 pathway.

Authors:  Scott N Pinchot; Joel T Adler; Yinggang Luo; Jianhua Ju; Wenli Li; Ben Shen; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  Am J Surg       Date:  2009-03       Impact factor: 2.565

10.  Development and characterization of a novel in vivo model of carcinoid syndrome.

Authors:  Lindsey N Jackson; L Andy Chen; Shawn D Larson; Scott R Silva; Piotr G Rychahou; Paul J Boor; Jing Li; Gilberto Defreitas; W Lane Stafford; Courtney M Townsend; B Mark Evers
Journal:  Clin Cancer Res       Date:  2009-03-31       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.